- Home
- App Analytics
- Obvio Hub
- Obvio Hub Vs. PatienTrials
Obvio Hub vs PatienTrials Uso e estatísticas
Obvio Hub is a proprietary platform of ObvioHealth used to manage decentralized and hybrid clinical trials. The result? Robust data collection, increased compliance, faster time to completion, and average cost savings of ~50% vs. traditional on-site trials
The Obvio Hub app facilitates the successful and secure operation of virtual clinical trials by allowing the study team to monitor the trial's progress, view data insights, and complete trial tasks. The app provides the full range of functionality offered in the web interface.
- Apple App Store
- Gratuitos
- Saúde e fitness
Ranking da Loja
- -
PatienTrials helps pharma companies and clinicians run global clinical trials virtually, more efficiently in a closed community setting over HIPAA & GDPR compliant collaboration platform. PatienTrials aims to improve patient adherence by empowering participants with information on the progress of treatment at their fingertips in a community setting, that promotes self-care. PatienTrials captures high-quality patient generated data through solutions based on instant messaging, HealthKit, AI and bots, is poised to make a positive impact on drug development. Monitored by proprietary AI agent for adverse events, PatienTrials reduces study risk and lowers development costs. Founded in 2016, PatienTrials is the first company to bring clinical trials on to a HIPAA & GDPR compliant instant messaging platform.
- Apple App Store
- Gratuitos
- Médico
Ranking da Loja
- -
Obvio Hub versus PatienTrials comparação de classificação
Compare a tendência de classificação de Obvio Hub nos últimos 28 dias versus PatienTrials
Classificação
Nenhum dado disponível
Comparação da classificação de Obvio Hub vs. PatienTrials por país
Compare a tendência de classificação de Obvio Hub nos últimos 28 dias versus PatienTrials
Nenhum dado para exibir
Faça comparações com qualquer site com o nosso teste grátis
Obvio Hub VS.
PatienTrials
18ezembro d, 2024